Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALM: Lopinavir/Ritonavir and Maraviroc in HIV-experienced patients
NCT00981318Phase 4Terminated
- Start
- Dec 2009
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lopinavir + ritonavir and maraviroc in human immunodeficiency virus infection (HIV). Primary endpoint: Virologic response defined as viral load reduction of >= 1 log at 48 weeks. Started Dec 2009; status: terminated.
02
Drugs
lopinavir + ritonavirmaraviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00981318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00981318.